Blueprint Medicines Corporation | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (31)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Article By: ChinaBio® Today
Saturday, July 1, 2023 2:58 PM EDT
Cellular Biomedicine Group out-licensed global rights to its two lead CAR-T candidates to Janssen Biotech for $245 million upfront, plus milestones. Also, Shanghai Laekna Therapeutics completed an IPO on the Hong Kong Exchange, raising $100 million.
In this article: MRK, NVS, SGIOY, BPMC, IVBXF, REGMF, BRIBF
Read
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Article By: ChinaBio® Today
Saturday, July 16, 2022 1:40 PM EDT
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. The USD Fund VIII has $2.5 billion and the first round of RMB Fund VII closed at RMB 4.7 billion.
In this article: LLY, 600535.SS, SHTDF, BPMC, 2616.HK, CNTB
Read
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
Article By: ChinaBio® Today
Saturday, November 13, 2021 2:15 PM EDT
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
In this article: 600566.SS, BPMC, ZLAB, KRTX, IMAB, 1672.HK, 9966.HK, 1952.HK, 326030.KS
Read
Biotech Deal Sparks Rally
Article By: Rod Raynovich
Wednesday, February 14, 2018 5:32 PM EDT
Biopharmaceutical stocks rallied broadly with big large-cap movers: ALXN, AMGN, RHHBY; and mid-caps ALKS, BLUE, BPMC, NBIX and SGEN. Smaller caps were wildly up.
In this article: BMY, NAZ, RHHBY, ALXN, IBB, SGEN, ALKS, AMGN, NBIX, NKTR, FBT, XBI, BLUE, BPMC
Read
Biotech Bounce “Ignyted” By Roche Deal
Article By: Rod Raynovich
Friday, December 22, 2017 3:07 PM EDT
Biotech stocks escaped the doldrums today ignited by Roche (RHHBY) acquisition of Ignyta, Inc. (RXDX) for $1.7B in an all-cash transaction.
In this article: RHHBY, RXDX Also: ARRY, IBB, CELG, EXEL, SAGE, GLYC, AGIO, TSRO, EDIT, BPMC
Read
All Posts

Latest Tweets for $BPMC

No tweets yet!

PARTNER HEADLINES